These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36517738)

  • 1. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
    Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
    BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
    Pedrero Prieto M; Gorriz Romero D; Gómez Roch E; Pérez Miralles FC; Casanova Estruch B
    Neurol Sci; 2024 May; 45(5):2199-2202. PubMed ID: 38091210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
    Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
    Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
    Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
    Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
    BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach.
    Dinoto A; Borin GU; Campana G; Carta S; Ferrari S; Mariotto S
    Eur J Neurol; 2022 Nov; 29(11):3466-3472. PubMed ID: 35767391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
    Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
    Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
    Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
    Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of organizing pneumonia in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
    Furube A; Kadota T; Gochi M; Saito S; Shibata S; Inaki S; Tone K; Takagi M; Matsuno H; Araya J; Yaguchi H; Kuwano K
    Respir Investig; 2022 Sep; 60(5):684-693. PubMed ID: 35871065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
    Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders.
    Iorio R; Papi C
    Handb Clin Neurol; 2021; 181():173-186. PubMed ID: 34238456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
    Iorio R; Rindi G; Erra C; Damato V; Ferilli M; Sabatelli M
    Mult Scler; 2015 May; 21(6):791-4. PubMed ID: 25716881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
    Abdel-Mannan O; Klein A; Bachar Zipori A; Ben-Sira L; Fattal-Valevski A; Hacohen Y; Meirson H
    Mult Scler; 2022 Apr; 28(4):676-679. PubMed ID: 35332817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature.
    Spiezia AL; Carotenuto A; Iovino A; Moccia M; Gastaldi M; Iodice R; Tedeschi E; Petracca M; Lavorgna L; d'Ambrosio A; Brescia Morra V; Lanzillo R
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.